


**We claim:**

1. A compound having the general formula Ib:



wherein

X, Y and Z are CH;

o is 0; n is 0; m is 0, 1, 2, 3 or 4;

A is C=O


W is NH;

R<sup>2</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, -OH, -OR<sup>5</sup>, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkyl, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>5</sup>)<sub>2</sub>, -C(O)R<sup>5</sup>, -C(O)OR<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -SR<sup>5</sup>, -S(O)R<sup>5</sup>, -S(O)<sub>2</sub>R<sup>5</sup>, -S(O)<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R<sup>3</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, hydroxyl, -OR<sup>6</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>6</sup>)C(O)R<sup>6</sup>, -C(O)R<sup>6</sup>, -C(O)OR<sup>6</sup>, -C(O)N(R<sup>6</sup>)<sub>2</sub>, -S(O)R<sup>6</sup>, -S(O)<sub>2</sub>R<sup>6</sup>, -S(O)<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, any of which is optionally substituted, or two groups of R<sup>3</sup> are connected to each other to make five or six membered cyclic and heterocyclic rings;

R<sup>5</sup> and R<sup>6</sup> are, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R<sup>10</sup> is a moiety selected from the group consisting of



wherein  $m'$  is 0, 1, 2, 3 or 4 and  $n'$  is 0, 1, 2, or 3;


















$R^{11}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl,  $-OH$ ,  $-OR^{13}$ ,  $C_1$ - $C_{10}$  alkoxy,  $C_3$ - $C_{10}$  cycloalkoxy,  $C_3$ - $C_{15}$  cycloalkylalkoxy,  $C_3$ - $C_{15}$  cycloalkylalkyl,  $-NH_2$ ,  $-N(R^{13})_2$ ,  $-C(O)R^{13}$ ,  $-C(O)OR^{13}$ ,  $-C(O)N(R^{13})_2$ ,  $-S(O)R^{13}$ ,  $-S(O)_2R^{13}$ ,  $-S(O)_2N(R^{13})_2$ , aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;













$R^{12}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, hydroxyl,  $-OR^{14}$ ,  $-C(O)R^{14}$ ,  $-C(O)OR^{14}$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-N(R^{14})_2$ ,  $-C(O)N(R^{14})_2$ ,  $-S(O)R^{14}$ ,  $-S(O)_2R^{14}$ ,  $-S(O)_2N(R^{14})_2$ , aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;



$R^{13}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl; and


$R^{14}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_8$  alkyl optionally substituted with at least one hydroxyl or halogen;  $C_3$ - $C_7$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl.

2. The compound as claimed in claim 1, having one of the formulae 1-352,












**164**




**165**




**166**




**167**




**168**




**169**




**170**




**171**




**172**




**173**




**174**




**175**




**176**




**177**




**178**




**179**




**180**




**181**




**183**




















**193**












**194**




**195**









**265**




**266**




**267**




**268**





















**269**





















**270**





















**271**








































preferably one of the formulae, 56, 66-69, 74, 77-80, 89-91, 110, 111, 113, 139, 140, 144, 162-167, 171-182, 193, 209-218, 221-225, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324.

3. A compound having one of the formulae 17, 56, 58, 59, 66-69, 74, 77-80, 89-91, 108-115, 139, 140, 144, 162-181, 183, 193-195, 204-225, 265-329, and 331-352 as shown in claim 2, preferably one of the formulae 56, 66-69, 74, 77-80, 89-91, 110, 111, 113, 139, 140, 144, 162-167, 171-181, 193, 209-218, 221-225, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324.

4. The compound as claimed in claim 1, having formula 177.

5. A compound having the general formula Ib:



wherein

X, Y and Z are CH;

o is 1; n is 0; m is 1, 2, 3 or 4;

A is C=O;


W is NH;

R<sup>2</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, -OR<sup>5</sup>, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkyl, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>5</sup>)<sub>2</sub>, -C(O)R<sup>5</sup>, -C(O)OR<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -SR<sup>5</sup>, -S(O)R<sup>5</sup>, -S(O)<sub>2</sub>R<sup>5</sup>, -S(O)<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, and heterocyclyl;

R<sup>3</sup> is, at each occurrence, independently selected from the group consisting of halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, hydroxyl, -OR<sup>6</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>6</sup>)C(O)R<sup>6</sup>, -C(O)R<sup>6</sup>, -C(O)N(R<sup>6</sup>)<sub>2</sub>, -S(O)R<sup>6</sup>, -S(O)<sub>2</sub>R<sup>6</sup>, -S(O)<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, or two groups of R<sup>3</sup> are connected to each other to make five or six membered cyclic and heterocyclic rings,

R<sup>5</sup> and R<sup>6</sup> are, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R<sup>10</sup> is a moiety selected from the group consisting of



wherein  $m'$  is 0, 1, 2, 3 or 4 and  $n'$  is 0, 1, 2, or 3;

$R^{11}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, -OH, -OR<sup>13</sup>,  $C_1$ - $C_{10}$  alkoxy,  $C_3$ - $C_{10}$  cycloalkoxy,  $C_3$ - $C_{15}$  cycloalkylalkoxy,  $C_3$ - $C_{15}$  cycloalkylalkyl, -NH<sub>2</sub>, -N(R<sup>13</sup>)<sub>2</sub>, -C(O)R<sup>13</sup>, -C(O)OR<sup>13</sup>, -C(O)N(R<sup>13</sup>)<sub>2</sub>, -S(O)R<sup>13</sup>, -S(O)<sub>2</sub>R<sup>13</sup>, -S(O)<sub>2</sub>N(R<sup>13</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

$R^{12}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, hydroxyl, -OR<sup>14</sup>, -C(O)R<sup>14</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>14</sup>)<sub>2</sub>, -C(O)N(R<sup>14</sup>)<sub>2</sub>, -S(O)R<sup>14</sup>, -S(O)<sub>2</sub>R<sup>14</sup>, -S(O)<sub>2</sub>N(R<sup>14</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

$R^{13}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, and

$R^{14}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_8$  alkyl optionally substituted with at least one hydroxyl or halogen;  $C_3$ - $C_7$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl.

6. A pharmaceutical composition comprising a compound as claimed in any of claims 1 –5, and a pharmaceutically acceptable carrier.


Dated 10<sup>th</sup> day of July, 2019



**KAVITA ARORA  
OF K & S PARTNERS  
AGENT FOR THE APPLICANT(S)  
IN/PA-2160**

**We claim:**

1. A compound having the general formula Ia:



wherein

m is 0, 1, 2, 3 or 4;

n is 0, 1, 2, or 3;

X, Y and Z are CH, N or N-oxide;

$R^1$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub>-alkyl, C<sub>1</sub>-C<sub>3</sub>-haloalkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, hydroxyl, oxo, OR<sup>4</sup>, C(O)OR<sup>4</sup>, C(O)R<sup>4</sup>, C(O)N(R<sup>4</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, N(R<sup>4</sup>)<sub>2</sub>, OR<sup>4</sup>HetA, OR<sup>4</sup>N(R<sup>4</sup>)<sub>2</sub>, C(O)N(R<sup>4</sup>)R<sup>4</sup>HetA, C(O)N(R<sup>4</sup>)HetA, C(O)HetA, C(O)N(R<sup>4</sup>)R<sup>4</sup>S(O)<sub>2</sub>R<sup>4</sup>, S(O)<sub>2</sub>N(R<sup>4</sup>)<sub>2</sub>, S(O)<sub>2</sub>R<sup>4</sup>, N(R<sup>4</sup>)C(O)R<sup>4</sup>SR<sup>4</sup>, N(R<sup>4</sup>)R<sup>4</sup>S(O)<sub>2</sub>R<sup>4</sup>, N(R<sup>4</sup>)S(O)<sub>2</sub>R<sup>4</sup>, C(S)R<sup>4</sup>, aryl, e.g. phenyl, benzyl, and heterocyclyl, any of which is optionally substituted;

$R^2$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub>-alkyl, C<sub>3</sub>-C<sub>10</sub>-cycloalkyl, C<sub>2</sub>-C<sub>10</sub>-alkenyl, C<sub>3</sub>-C<sub>10</sub>-cycloalkenyl, C<sub>2</sub>-C<sub>10</sub>-alkynyl, C<sub>1</sub>-C<sub>10</sub>-haloalkyl, OH, OR<sup>5</sup>, C<sub>1</sub>-C<sub>10</sub>-alkoxy, C<sub>3</sub>-C<sub>10</sub>-cycloalkoxy, C<sub>3</sub>-C<sub>15</sub>-cycloalkylalkoxy, C<sub>3</sub>-C<sub>15</sub>-cycloalkylalkyl, CN, NO<sub>2</sub>, NH<sub>2</sub>, N(R<sup>5</sup>)<sub>2</sub>, C(O)R<sup>5</sup>, C(O)OR<sup>5</sup>, C(O)N(R<sup>5</sup>)<sub>2</sub>, SR<sup>5</sup>, S(O)R<sup>5</sup>, S(O)<sub>2</sub>R<sup>5</sup>, S(O)<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, any of which is optionally substituted;


$R^3$  is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub>-alkyl, C<sub>3</sub>-C<sub>10</sub>-cycloalkyl, hydroxyl, OR<sup>6</sup>, CN, NO<sub>2</sub>, NH<sub>2</sub>, N(R<sup>6</sup>)C(O)R<sup>6</sup>, C(O)R<sup>6</sup>, C(O)OR<sup>6</sup>, C(O)N(R<sup>6</sup>)<sub>2</sub>, S(O)R<sup>6</sup>, S(O)<sub>2</sub>R<sup>6</sup>, S(O)<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, any of which is optionally substituted, or two groups of R<sup>3</sup> are connected to each other to make five or six membered cyclic and heterocyclic rings, any of which is optionally substituted;

~~R<sup>4</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>4</sub>-C<sub>10</sub> haloalkyl, —C(O)R<sup>7</sup>, —R<sup>7</sup>(R<sup>7</sup>)C(O)R<sup>7</sup>, —C(O)OR<sup>7</sup>, —R<sup>7</sup>(R<sup>7</sup>)C(O)OR<sup>7</sup>, —C(O)N(R<sup>7</sup>)<sub>2</sub>, —R<sup>7</sup>(R<sup>7</sup>)C(O)N(R<sup>7</sup>)<sub>2</sub>, —S(O)R<sup>7</sup>, —S(O)<sub>2</sub>R<sup>7</sup>, —S(O)<sub>2</sub>N(R<sup>7</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, any of which is optionally substituted; and~~

~~R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>4</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, any of which is optionally substituted;~~

~~and pharmaceutically acceptable salts thereof.~~

~~21. The A compound according to claim 1, having the general formula Ib:~~




wherein

X, Y and Z are CH;

o is 0, 1, 2, or 3; n is 0, 1, 2 or 3; m is 0, 1, 2, 3 or 4;

A is NR<sup>++</sup>, C=O, C=S, OP(O), P=O, CH<sub>2</sub>, or a heteroaryl selected from the group consisting of



W is NH-C=O, O, S, CH<sub>2</sub> or NR<sup>++</sup>;


R<sup>2</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, -OH, -OR<sup>5</sup>, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkoxy,

C<sub>3</sub>-C<sub>15</sub> cycloalkylalkyl, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>5</sup>)<sub>2</sub>, -C(O)R<sup>5</sup>, -C(O)OR<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -SR<sup>5</sup>, -S(O)R<sup>5</sup>, -S(O)<sub>2</sub>R<sup>5</sup>, -S(O)<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R<sup>3</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, hydroxyl, -OR<sup>6</sup>, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>6</sup>)C(O)R<sup>6</sup>, -C(O)R<sup>6</sup>, -C(O)OR<sup>6</sup>, -C(O)N(R<sup>6</sup>)<sub>2</sub>, -S(O)R<sup>6</sup>, -S(O)<sub>2</sub>R<sup>6</sup>, -S(O)<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, any of which is optionally substituted, or two groups of R<sup>3</sup> are connected to each other to make five or six membered cyclic and heterocyclic rings;

R<sup>5</sup> and R<sup>6</sup> are, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R<sup>10</sup> is a moiety selected from the group consisting of



wherein m' is 0, 1, 2, 3 or 4 and n' is 0, 1, 2, or 3;





$R^{11}$  is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, -OH, -OR<sup>13</sup>, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkyl, -NH<sub>2</sub>, -N(R<sup>13</sup>)<sub>2</sub>, -C(O)R<sup>13</sup>, -C(O)OR<sup>13</sup>, -C(O)N(R<sup>13</sup>)<sub>2</sub>, -S(O)R<sup>13</sup>, -S(O)<sub>2</sub>R<sup>13</sup>, -S(O)<sub>2</sub>N(R<sup>13</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, ~~any of which is optionally substituted~~;
















$R^{12}$  is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, hydroxyl, -OR<sup>14</sup>, -C(O)R<sup>14</sup>, ~~R<sup>14</sup>(R<sup>14</sup>)C(O)R<sup>14</sup>~~, -C(O)OR<sup>14</sup>, ~~R<sup>14</sup>(R<sup>14</sup>)C(O)OR<sup>14</sup>~~, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>14</sup>)<sub>2</sub>, -C(O)N(R<sup>14</sup>)<sub>2</sub>, ~~R<sup>14</sup>(R<sup>14</sup>)C(O)N(R<sup>14</sup>)<sub>2</sub>~~, -S(O)R<sup>14</sup>, -S(O)<sub>2</sub>R<sup>14</sup>, -S(O)<sub>2</sub>N(R<sup>14</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, ~~any of which is optionally substituted~~;













$R^{13}$  is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, ~~any of which is optionally substituted~~; and


$R^{14}$  is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with at least one hydroxyl or halogen; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl, ~~any of which is optionally substituted~~.

3-2. The compound ~~as claimed in according to~~ claim 1 ~~or 2~~, having one of the formulae 1-352 ~~as shown in Table 1~~,












164




165




166




167




168




169




170




171




172




173




174




175




176




177




178







179



























180






















181



















**183****193****194****195**




























































preferably one of the formulae 15, 16, 31, 32, 44, 45, 47, 49, 54-57, 56, 60-87-66-69, 74, 77-80,

89-91 103, 106, 107, 110, 111, 113, 116-135, 137-141, 139, 140, 143, 144, 147, 148, 152, 154, 157-159, 161-162-167, 171-182, 184-193, 196, 198, 199-202, 209-218, 221-227-225, 231, 248-260, 262-264, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324, and 330 as shown in Table 1,

and pharmaceutically acceptable salts thereof.

3. A compound having one of the formulae 17, 56, 58, 59, 66-69, 74, 77-80, 89-91, 108-115, 139, 140, 144, 162-181, 183, 193-195, 204-225, 265-329, and 331-352 as shown in claim 2,

preferably one of the formulae 56, 66-69, 74, 77-80, 89-91, 110, 111, 113, 139, 140, 144, 162-167, 171-181, 193, 209-218, 221-225, 267-269, 271-274, 280-293, 295-315, 317-318, 320-321, and 324.


~~4. The compound as claimed in according to any of claims 1—3~~claim 1, having ~~one of the formulae 47, 54, 177 and 185 as shown in Table 1,~~

~~and pharmaceutically acceptable salts thereof.~~

~~5. The compound according to any of claims 1—4, for use in the treatment of a bacterial infection.~~

~~6. The compound according to claim 5, wherein said bacterial infection is Tuberculosis.~~

5. A compound having the general formula Ib:



Ib

wherein

X, Y and Z are CH;

o is 1; n is 0; m is 1, 2, 3 or 4;

A is C=O;


W is NH;

R<sup>2</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, -OR<sup>5</sup>, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>3</sub>-C<sub>10</sub> cycloalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkoxy, C<sub>3</sub>-C<sub>15</sub> cycloalkylalkyl, -CN, -NO<sub>2</sub>, -NH<sub>2</sub>, -N(R<sup>5</sup>)<sub>2</sub>, -C(O)R<sup>5</sup>, -C(O)OR<sup>5</sup>, -C(O)N(R<sup>5</sup>)<sub>2</sub>, -SR<sup>5</sup>, -S(O)R<sup>5</sup>, -S(O)<sub>2</sub>R<sup>5</sup>, -S(O)<sub>2</sub>N(R<sup>5</sup>)<sub>2</sub>, aryl, e.g. phenyl, benzyl, and heterocyclyl;

$R^3$  is, at each occurrence, independently selected from the group consisting of halogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl, hydroxyl,  $-OR^6$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-N(R^6)C(O)R^6$ ,  $-C(O)R^6$ ,  $-C(O)N(R^6)_2$ ,  $-S(O)R^6$ ,  $-S(O)_2R^6$ ,  $-S(O)_2N(R^6)_2$ , aryl, e.g. phenyl, benzyl, heteroaryl, heterocyclyl, or two groups of  $R^3$  are connected to each other to make five or six membered cyclic and heterocyclic rings.

$R^5$  and  $R^6$  are, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

$R^{10}$  is a moiety selected from the group consisting of



wherein  $m'$  is 0, 1, 2, 3 or 4 and  $n'$  is 0, 1, 2, or 3;

$R^{11}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl,  $-OH$ ,  $-OR^{13}$ ,  $C_1$ - $C_{10}$  alkoxy,  $C_3$ - $C_{10}$  cycloalkoxy,  $C_3$ - $C_{15}$  cycloalkylalkoxy,  $C_3$ - $C_{15}$  cycloalkylalkyl,  $-NH_2$ ,  $-N(R^{13})_2$ ,  $-C(O)R^{13}$ ,  $-C(O)OR^{13}$ ,  $-C(O)N(R^{13})_2$ ,  $-S(O)R^{13}$ ,  $-S(O)_2R^{13}$ ,  $-S(O)_2N(R^{13})_2$ , aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

$R^{12}$  is, at each occurrence, independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_3$ - $C_{10}$  cycloalkyl,  $C_2$ - $C_{10}$  alkenyl,  $C_3$ - $C_{10}$  cycloalkenyl,  $C_2$ - $C_{10}$  alkynyl,  $C_1$ - $C_{10}$  haloalkyl, hydroxyl,  $-OR^{14}$ ,  $-C(O)R^{14}$ ,  $-CN$ ,  $-NO_2$ ,  $-NH_2$ ,  $-N(R^{14})_2$ ,  $-C(O)N(R^{14})_2$ ,  $-S(O)R^{14}$ ,  $-S(O)_2R^{14}$ ,  $-S(O)_2N(R^{14})_2$ , aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl;

R<sup>13</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>3</sub>-C<sub>10</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl, and heterocyclyl, and

R<sup>14</sup> is, at each occurrence, independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl optionally substituted with at least one hydroxyl or halogen; C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>2</sub>-C<sub>10</sub> alkenyl, C<sub>3</sub>-C<sub>10</sub> cycloalkenyl, C<sub>2</sub>-C<sub>10</sub> alkynyl, C<sub>1</sub>-C<sub>10</sub> haloalkyl, aryl, e.g. phenyl, benzyl, heteroaryl and heterocyclyl.

~~76. A pharmaceutical composition comprising a compound as claimed in according to any of claims ~~1—6~~1—5, and a pharmaceutically acceptable carrier.~~

~~8. A method of treatment of a bacterial infection, in particular Tuberculosis, comprising the application of a suitable amount of a compound according to any of claims ~~1—6~~ or a pharmaceutical composition according to claim ~~7~~, to a person in need thereof.~~

~~9. A compound that competitively inhibits the specific binding of a compound according to any of claims ~~1—6~~.~~

~~10. A method of treatment of a bacterial infection, in particular Tuberculosis, comprising the application of a suitable amount of a compound, which compound is characterized by an ability to competitively inhibit the specific binding of a compound according to any of claims ~~1—6~~ or a pharmaceutical composition according to claim ~~7~~, to its target protein, to a person in need thereof.~~